Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease

Somang Kang; Yong-ho Lee; Jong Eun Lee

doi:10.3349/ymj.2017.58.3.479

Journal List > Yonsei Med J > v.58(3) > 1032144

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kang, Lee, and Lee: Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease

Review Article

Yonsei Medical Journal 2017; 58(3): 479-488.

Published online: 15 March 2017

DOI: https://doi.org/10.3349/ymj.2017.58.3.479

Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease

Somang Kang^1,², Yong-ho Lee³, Jong Eun Lee^1,²

¹Department of Anatomy, Yonsei University College of Medicine, Seoul, Korea.

²BK21 Plus Project for Medical Sciences and Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea.

³Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Dr. Jong Eun Lee, Department of Anatomy, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: 82-2-2228-1646, Fax: 82-2-365-0700, jelee@yuhs

Received 13 February 2017

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia. AD is characterized by the extracellular amyloid beta (Aβ) plaques and intraneuronal deposits of neurofibrillary tangles (NFTs). Recently, as aging has become a familiar phenomenon around the world, patients with AD are increasing in number. Thus, many researchers are working toward finding effective therapeutics for AD focused on Aβ hypothesis, although there has been no success yet. In this review paper, we suggest that AD is a metabolic disease and that we should focus on metabolites that are affected by metabolic alterations to find effective therapeutics for AD. Aging is associated with not only AD but also obesity and type 2 diabetes (T2DM). AD, obesity, and T2DM share demographic profiles, risk factors, and clinical and biochemical features in common. Considering AD as a kind of metabolic disease, we suggest insulin, adiponectin, and antioxidants as mechanistic links among these diseases and targets for AD therapeutics. Patients with AD show reduced insulin signal transductions in the brain, and intranasal injection of insulin has been found to have an effect on AD treatment. In addition, adiponectin is decreased in the patients with obesity and T2DM. This reduction induces metabolic dysfunction both in the body and the brain, leading to AD pathogenesis. Oxidative stress is known to be induced by Aβ and NFTs, and we suggest that oxidative stress caused by metabolic alterations in the body induce brain metabolic alterations, resulting in AD.

Keywords: Alzheimer's disease, insulin, adiponectin, antioxidants, metabolic disease

INTRODUCTION

Recently, aging has become a familiar phenomenon around the world. Aging societies are faced with various chronic diseases, such as Alzheimer's disease (AD), obesity, and type 2 diabetes (T2DM). Globally, an estimated 422 million adults over the age of 18 years suffered with diabetes in 2014, and 5.3 million Americans of all ages were diagnosed with AD in 2015.1 According to the 2012 Korean Epidemiological Survey of Dementia, around 530 thousands Koreans older than 65 years were diagnosed with AD, with an estimated two-fold increase therein every 20 years. Interestingly, obesity, T2DM, and AD are reported to be related with each other.2

AD is a degenerative brain disease and the most common cause of dementia. AD is characterized by extracellular amyloid beta (Aβ) plaques and intraneuronal deposits of neurofibrillary tangles (NFTs). NFTs are constituted by hyperphosphorylated tau proteins, whereas Aβ plaques are insoluble and aggregated form of Aβ peptide.3 Until now, therapeutics for AD has been focused mostly on Aβ, with little success. Development of AD treatment could potentially benefit from seeking to consider the relationships among AD, obesity, and T2DM.

According to the Mayo Clinic Alzheimer Disease Patient Registry, 80% of AD patients show impairment in glucose tolerance or have diabetes.4 Epidemiological studies have demonstrated that T2DM induces cognitive impairment and that patients with T2DM are more likely to be diagnosed with dementia by 1.5- to 2-fold.5 Also, increasing evidence has shed light on cellular insulin resistance or insulin insufficiency in the brains of AD patients, including those without having diabetes, thus AD is often referred to as “type 3 diabetes”.6

Obesity is generally defined by a body mass index (BMI) over 30 kg/m² (25 kg/m² in Korea) and is usually caused by physical inactivity and westernized diet habits. Obesity is an important risk factor for various diseases, ranging from metabolic diseases to neurodegenerative diseases. As obesity causes insulin resistance, it is one of the major risk factor for T2DM. After years of hyperinsulinemia, insulin secretory function in the pancreas can falter, causing patients to suffer from relative hypoinsulinemia, which leads to hyperglycemia.7

A large number of research has proven that obesity in middle age individuals can be an index of mild cognitive impairment at later years.8 Even when controlling for aging, studies have shown a negative correlation between BMI and global cognitive performance.9 T2DM has also been linked to reduced cognitive function and an increased risk for developing dementia, including AD.10

AD, obesity, and T2DM share similar demographic profiles, risk factors, and clinical and biochemical features.11 These conditions are associated with chronic inflammation, severe oxidative stress, and impairment in insulin signaling and energy metabolism.12 Interestingly, people with diets high in cholesterol, saturated fats, and total calories have been found to be at greater risk for AD than people who regularly eat fiber, vegetables, and fruits.13 Animal studies have also demonstrated that a high-fat diet causes AD pathology, including accumulation of Aβ and phosphorylated tau proteins, as well as cognitive impairment.14 15

Given the relationship among obesity, T2DM, and AD, understanding the mechanistic links among them is essential to developing effective strategies for AD prevention and treatment. Until now, inflammation has been thought to link obesity, T2DM, and AD.1 16 Considering AD as a metabolic disease, however, we suggest that metabolic alterations could be the primary mechanistic links among these diseases. Therefore, the specific goal of this review paper was to investigate proper therapeutic targets for treating AD from our point of view that AD is a metabolic disease.

ALZHEIMER'S DISEASE: METABOLIC ALTERATIONS IN THE BRAIN

AD is a degenerative disease that impairs cognition and memory and is a leading cause of dementia. Alois Alzheimer, for whom AD is named, described the pathology of the disease as an extensive distribution of neuronal tangles and amyloid pl-aques in the brain, which are considered hallmarks of the disease.3 Aβ accumulation is thought to initiate AD by destroying synapses causing neuron loss, a process known as amyloid hypothesis. Amyloid hypothesis has become the dominant model of AD pathogenesis and has guided the development of potential treatments for AD.17

However, clinical studies have documented several inconsistencies in AD pathology. Around 99.6% of drug candidates targeting amyloid pathways, such as beta secretase inhibitors, gamma secretase inhibitors, and Aβ itself, have failed.18 In addition, a weak correlation between Aβ deposition and cognitive decline have been reported.19 For example, Aβ deposits are observed in the medial prefrontal cortex at early stages of AD. Then, these deposits expand into the medial temporal lobe, including the hippocampus. However, cognitive function begins to decline in an opposite way, starting from the medial temporal lobe to the medial prefrontal cortex.20

Recently, early selective atrophy and alteration of glucose metabolism were discovered in the medial temporal lobe of patients with AD using imaging tools.21 In addition, in Alzheimer's disease, degeneration of the basal forebrain cholinergic neurons and a decrease in brain glucose metabolism are characteristically observed.22 With two functional brain imaging techniques, the [¹⁸F] 2-fluoro-2-deoxy-D-glucose positron emission tomography and functional magnetic resonance imaging, alterations of glucose metabolism in the brain have begun to receive attention as a feasible cause for AD.23 Interestingly, patients with AD have been found to display increased lactate levels in cerebrospinal fluid (CSF), resulting from metabolic dysfunction;24 however, this type of metabolic alteration has only now been considered as a characteristic of AD.

Aging plays critical roles in neurodegenerative disease and metabolism and is an important cause of AD. As an individual's metabolism gets weaker with age, metabolic alterations are feasible consequences of aging and potential causes of AD. Indeed, imaging studies have shown that a person aged over 70 years could have presymptomatic AD if individuals exhibit dysregulation in glucose metabolism, even though they may show normal cognition at present.25 However, amyloid hypothesis considers AD as a disease determined exclusively by the genomic instability not by metabolic alterations.26

There are two types of cells in the brain, neuron and glial cells, and they are reported to be related with many components of metabolism, called neuron-astrocyte shuttle hypothesis.27 Both cells make use of glucose as a primary energy source, although they metabolize glucose in different ways. In astrocytes, most glucose is metabolized to lactate anaerobically, and then, lactate is released into the extracellular space. In neurons, pyruvate derived from glucose or lactate is metabolized under aerobic conditions, and the energy is produced mainly by oxidative phosphorylation in the mitochondria. Because neurons do not have enough activated glycolysis prompting enzymes, neurons are inclined to not process glucose through glycolysis.28

Due to aging, mitochondria can malfunction, resulting in excessive increases in oxidative stress, as well as oxidative phosphorylation, in the brain.29 Increased mitochondrial oxidative activity demands more energy substrates to produce energy, such that there is an energy shortage in the whole body even though the other cells that have not experienced increased oxidative activity including the brain suffer energy shortage.30 Thereby, some neurons are unable to occupy energy substrates and produce enough energy. Lacking energy, these neurons cannot survive and cause dementia.

Metabolic diseases, such as T2DM and obesity, are reported to be related with AD, meaning that AD is a kind of metabolic disease (Fig. 1). Therefore, metabolic alteration could be potential cause of AD, such that various substances (insulin, adiponectin, and antioxidants) that are influenced by metabolic alterations could be therapeutic targets for AD.

ALZHEIMER'S DISEASE: BRAIN INSULIN RESISTANCE

Considering the prevalences with which T2DM and AD occur, the idea that patients with T2DM could be at higher risk for AD has garnered greater acceptance. In addition, patients with T2DM have been found to be at a two-fold higher risk for AD and to be diagnosed with mild cognitive impairment in a comparably shorter time.31 Hyperglycemia has also been found to accelerate cognitive decline.32 As the brain is likely to encounter defective insulin signaling with increasing age,33 researchers have begun to study mechanistic links between these diseases; the most promising link has been insulin.34

Insulin is a major anabolic hormone that is secreted from pancreas beta cells in response to high glucose levels. Insulin signals by binding to insulin receptors, thereby activating insulin receptor substrate 1, extracellular signal-related kinase/mitogen activated protein kinase, and PI3 kinase/Akt pathways. Insulin also inhibits glycogen synthase kinase-3 (GSK-3).35 Through these signals, insulin maintains glucose homeostasis by regulating glucose production from the liver and glucose consumption by muscle and adipose tissue via GLUT4 translocation. Accordingly, impairment of insulin secretion or function is considered a primary cause of diabetes.36

Insulin resistance refers to the reduced ability of insulin on target tissues, including liver, muscle, and fat tissues. Specifically, insulin receptors' ability to transmit downstream signals or the ability of insulin to activate insulin receptors are reduced in insulin responsive tissues, and these phenomena have been considered as a hallmark feature of T2DM.37 While the vital role of insulin in the periphery is well recognized and has been extensively studied, the function of insulin in the central nervous system has only recently been studied.

Due to the large size of insulin peptide, it was thought that insulin is unable to cross the brain blood barrier (BBB), such that the brain was regarded as an insulin-independent organ.38 However, several studies have revealed that insulin receptors are abundantly distributed throughout the brain, proposing some mechanisms to explain the existence of insulin in the brain.39 Currently, insulin has been shown to be transported across the BBB through a carrier-mediated, saturable, and temperature- sensitive active process.40

All tissues and cell types, including neurons, have conserved insulin-signaling pathways.41 As shown in Fig. 2A, insulin participates in neuromodulation to regulate the concentrations of neurotransmitters, such as acetylcholine,42 repair, neuronal differentiation, proliferation, regeneration, and inhibition of neuronal apoptosis.43 Through downstream cascade, insulin mediates long-term potentiation, learning, and memory processes.44 45 Insulin signaling in specific brain regions, such as the limbic system and hypothalamus, has been found to be necessary for cognitive function.46

Interestingly, patients with diabetes also show insulin resistance in the brain.47 As Fig. 2B describes, reduced insulin action causes AD like alterations in the brain.48 In turn, Aβ oligomers initiate to remove insulin receptors from plasma membranes.49 Following these discoveries, insulin has been measured in postmortem brain tissue from AD patients, showing relatively low levels of insulin.50 Previously, we demonstrated that long-term high fat diet induces T2DM with insulin resistance both in the body and the brain, as well as AD pathologies, such as cognitive defects, accumulation of Aβ, and hyperphosphorylated tau in ICR mice.51

Insulin affects Aβ accumulation and the phosphorylation of tau as well. Insulin-degrading enzyme (IDE) is known to degrade excess insulin and other substrates, such as Aβ (Fig. 2). IDE knockout mice display accumulation of Aβ, hyperinsulinemia, and hyperglycemia.52 As insulin levels are raised, IDE expression is activated to prevent the long-term activation of insulin. However, when IDE is occupied with excess insulin, IDE cannot degrade Aβ, leading to the formation of senile plaques.53

GSK-3 has been most extensively studied as a kinase for tau, although it is also involved in Aβ production.54 GSK-3 is a multifunctional serine/threonine kinase that is affected by both the phosphorylation and aggregation of tau. One study has revealed that inhibition of GSK-3 improves learning and memory and decreases phosphorylation of tau in AD transgenic mouse models.55 We also demonstrated that GSK-3 is inhibited in the brain of mice with AD pathologies.51

Notably, intranasal administration of insulin has been found to help normal adults with improved memory by maintaining their serum insulin and glucose levels.56 Furthermore, intranasal insulin treatment has been shown to enhance cognitive performance in early AD patients,57 suggesting that insulin could be therapeutic target for AD.

ALZHEIMER'S DISEASE: REDUCED LEVELS OF ADIPONECTIN INDUCED BY OBESITY

The incidence of obesity is steadily rising throughout the world.58 Obesity can have damaging effects on many organ systems,59 because many changes induced by obesity are related to metabolic syndrome, characterized by excess weight, high triglyceride levels, and insulin resistance. Moreover, the incidences of cognitive decline and AD are increased with obesity.60

In normal adipose tissue, adipocytes secrete bioactive molecules, termed adipokines, including leptin, and adiponectin.61 Adipokines regulate several important physiological functions: for example, appetite, satiety, energy expenditure, insulin sensitivity and secretion, glucose and lipid metabolism, fat distribution, hemostasis, blood pressure, neuroendocrine regulation, and function of the immune system.62

In obesity, adipocytes become bigger, and hypertrophic adipocytes lead to the development of a pro-inflammatory environment. Hypertrophic adipocytes are often necrotic, and infiltration of macrophages is increased. Activated macrophages gather around necrotic adipocytes, where they secrete pro-inflammatory cytokines, such as TNF-α, IL-1β. This condition has systemic effects and is linked with the initiation of T2DM pathology.63

Among adipokines, adiponectin has beneficial effects on patients with T2DM and has been used in T2DM treatment due to its role of increasing insulin sensitivity.64 Adiponectin has been shown to enhance insulin sensitivity and several studies have reported the relationship between an increased prevalence of diabetes and decreased levels of adiponectin.65 Overexpression of adiponectin prevents high-fat diet-induced obesity in rodents, and genetically eliminating adiponectin in obese mice facilitates increased fat in the liver.66 Adiponectin reduces hepatic lipogenesis and increases β-oxidation through adiponectin receptor 1 (adipoR1)-mediated activation of adenosine monophosphate kinase (AMPK) and peroxisome proliferator-activated receptor α (PPAR α).67

While many researchers have maintained that adiponectin cannot cross the BBB, adiponectin is observed in CSF, and receptors for adiponectin are observed in the brain, suggesting the existence of adiponectin in the brain.68 As shown in Fig. 3A, adiponectin functions in the brain like insulin. As adiponectin receptors are expressed widely in the brain, including the hypothalamus, brainstem, cortex, and pituitary gland, adiponectin signaling pathways are activated in the brain and regulate energy expenditure, food intake, inflammation, cell death, and protection.69

Recently, the relationship between adiponectin and AD has begun to be studied. Some researchers have found a positive correlation between plasma and CSF adiponectin levels. Patients with mild cognitive impairment or AD have significantly higher plasma and CSF adiponectin levels than aged controls.70 However, some researchers found no significant differences in the plasma adiponectin levels between AD patients and non-AD controls. The exact relationship between adiponectin levels and the occurrence of AD remains unclear, although ongoing research suggests a complex association between AD and adiponectin.71

Because AMPK acts as a general energy sensor in the CNS,72 inhibition of adiponectin could affect brain metabolism (Fig. 3B). The local up-regulation of hypoxia inducible factor-1α (HIF-1α) in adipocytes in obese individuals is induced by hypoxic environment due to hypertrophic adipocytes.73 A study found that HIF-1α inhibits production of adiponectin. When adipocyte-specific HIF-1α knock-out mice were fed a high-fat diet for 7 weeks, they displayed high levels of adiponectin mRNA; meanwhile, control mice showed significantly low levels of adiponectin mRNA.74 These conditions could induce metabolic alteration in the brain and initiate pathology of AD.

As we mentioned above, a high fat diet can induce AD pathologies.14 15 To find a connection among HIF-1α, adiponectin, and AD, we fed a 60% high fat diet to 8 weeks old ICR mice for 24 weeks. These obese mice displayed cognitive decline and accumulation of Aβ and phosphorylated tau in the brain (under submission). We also revealed that 24 weeks of a high fat-diet induces reductions in the amounts of adiponectin and adipoR1, as well as increase in HIF-1α, in the brain, especially the cortex (Fig. 4).

Even though glucose and lactate are known as major energy sources in the brain, they are not enough to satisfy the energetic demands of the brain. A study revealed that the amount of glucose consumption and the levels of oxygen utilization in the brain are not matched.75 In terms of lactate, large amounts of lactate are unable to generate energy, because cells remove lactate very well and tissues that generate lactate consume most of it.76

After these discoveries, researchers found that fatty acids can enter the brain and mitochondria can oxidize them in the brain.77 Even though some studies have revealed that fatty acids are unable to be used as fuels for brain energy, mitochondrial oxidation of fatty acids provide energy to the brain, maximally 20% of its total energy.78 Furthermore, fatty acids play important roles in glucose homeostasis.79 Fatty acid metabolism is related with adiponectin, so that alterations of adiponectin could induce brain metabolism alteration and AD. Furthermore, adiponectin could be a potential therapeutic target for AD.

POSSIBLE CAUSE OF ALZHEIMER'S DISEASE: REDUCED ANTIOXIDANT DEFENSE MECHANISMS INDUCED BY VARIOUS METABOLIC ALTERATIONS

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are defined as reactive chemicals that have the capacity to donate electrons (e^-) to various molecules.80 In cells, ROS/RNS are produced through normal metabolism under aerobic physiological conditions.81 These species are generated under not only normal but also pathological conditions and result in oxidative stress, including nitrogen-based free radical species, as well as superoxide free radicals and hydrogen peroxide.82

Physiological levels of ROS/RNS play an important role in maintaining homeostasis and regulating signal transduction involved in proliferation and survival.83 Cellular antioxidant defense mechanisms regulate ROS/RNS production to maintain proper amounts thereof in normal environments. However, when ROS/RNS formation is dysregulated, oxidative stress disrupts cellular function and damages cells.82 84

Research indicates that Aβ causes oxidative stress. Aβ can form complexes with copper (Cu), generating hydrogen peroxide via Cu²⁺reduction.85 Aβ-induced oxidative stress disturbs cellular signaling and initiates a phosphorylation response, resulting in activated JNK, p38 MAPK, and hyperphosphorylated tau proteins in AD postmortem brains.86 Furthermore, since Aβ is generated from the cleavage of amyloid precursor proteins, located in trans membrane, it inserts into the bilayer of cells and initiates lipid peroxidation and a series of reactions, producing ROS.87

ROS levels are increased in obesity.88 Many studies have demonstrated that reduced insulin signals and adipokines dysregulation in T2DM patients leads to increased ROS production.89 Furthermore, high glucose levels are able to cause oxidative stress by various mechanisms, including glucose autoxidation, polyol pathway, advanced glycation end products formation, and PKCβ1/2 kinase.90 Increased free-radicals are able to attack unsaturated fatty acids oxidation in physiological systems. Obesity and T2DM patients have increased amounts of some by-products of lipid peroxidation, such as conjugated dienes and malondialdehyde.91

There are essential enzymes in antioxidant defense systems, such as glutathione reductase, glutathione S-transferase, and glutathione disulfide.92 T2DM patients show high oxidative da-mage and reduced antioxidant defenses mechanisms.93 Oxidative stress induced by various conditions, including abnormal superoxide dismutase and leaking mitochondria, is known to contribute to AD.94

In normal conditions, ROS is detoxified by producing succinate 95 via the stabilization of HIF-1α.96 When oxygen supply is adequate, mitochondrial lactate dehydrogenase in astrocytes is used to produce pyruvate and help in the synthesis of adenosine triphosphate. However, under ROS stress, these detoxification processes are unable to be effective. The process may lead towards lipid synthesis.97 Abnormal accumulation of lipid is commonly observed in patients with AD.98

Considering the noted relationships among obesity, T2DM, and AD, it is possible that increased ROS induced by metabolic alterations can cause AD pathologies (Fig. 5). There are several studies that demonstrate the effects of antioxidants on AD treatment. Various vitamins, such as Vitamin A, B, C, and K, are proven to be effective in AD treatment.99 We have also demonstrated the effect of agmatine, a polyamine that works as an antioxidant, on mice displaying AD like alterations induced by long term high-fat diet and rats with streptozotocin-induced AD.51 100 Oxidative stress is one of the most important factors involved in the development and progression of AD. Using antioxidants is a feasible approach that can help treat AD.

CONCLUSION

Conventional approaches to developing therapeutics for AD have focused on the Aβ hypothesis, which insists that Aβ causes AD pathologies. These approaches, however, have failed to treat or prevent AD. Through this review, we would like to suggest that metabolites, such as insulin, adiponectin, and ROS, could be therapeutic targets for developing effective treatments for AD, considering that metabolic alterations may be the primary causes of the disease.

Figures and Tables

Fig. 1

Alteration of brain metabolism causes Alzheimer's disease. Aging and metabolic diseases, such as obesity and diabetes, can alter brain metabolism. Alteration of brain metabolism progressively causes Alzheimer's disease.

Fig. 2

Brain insulin resistance causes Alzheimer's disease. (A) Insulin signaling maintains normal neuronal functions through IRS, ERK/MAPK, PI3K/AKT, and GSK3 signals. (B) Brain insulin resistance blunts insulin signal transduction, leading to neuronal cell death and Alzheimer's disease. IRS, insulin receptor substrate; ERK/MAPK, extracellular signal-related kinase/mitogen activated protein kinase; PI3K/AKT, PI3 kinase/Akt pathways; GSK3, glycogen synthase kinase-3; IDE, insulin-degrading enzyme; Aβ, amyloid beta.

Fig. 3

Reduced adiponectin levels induce brain metabolism alterations and consequently Alzheimer's disease. (A) Healthy adipose cells release adiponectin actively. Adiponectin regulates glucose metabolism and oxidases fatty acids in the brain in normal conditions. (B) Hypertrophic adipose cells induced by obesity elicit a pro-inflammatory environment and reduce adiponectin production. Reduced adiponectin causes energy shortages in the brain due to reduced fatty acid oxidation and dysregulated glucose metabolism. This induces brain metabolism alterations and progressively leads to Alzheimer's disease. HIF 1α, hypoxia inducible factor 1α.

Fig. 4

24 weeks of a high fat-diet causes decreases in adiponectin and adiponectin receptors and increases in HIF-1α in the brain. 8-week-old ICR mice were fed a 60% high fat diet for 24 weeks, and the levels of adiponectin, adipoR1 and HIF-1α were examined using western blot analysis. APN and adipoR1 were decreased in the cortices of the mice. HIF-1α increased in both the cortices and hippocampuses of the high fat-fed mice. Four mice were included in each group. ^*p<0.05. adipoR1, adiponectin receptor 1; HIF-1α, hypoxia inducible factor-1α; APN, adiponectin; HMW, high molecular weight; MMW, middle molecular weight; LMW, low molecular weight; ND, normal diet; HFD, high fat diet.

Fig. 5

Oxidative stress induces brain metabolism alterations, resulting in Alzheimer's disease. Persons suffering with metabolic diseases show higher levels of oxidative stress. Increased ROS causes brain metabolism alterations, such as fatty acids peroxidation and lipid synthesis, leading to progressive Alzheimer's disease. ROS, reactive oxygen species.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C2173). The authors would like to thank Dong-Su Jang, MFA (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, Korea) for his help with the illustrations.

Notes

The authors have no financial conflicts of interest.

References

1. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015; 11:332–384.

2. Kim DH. Epidemiology of dementia in Korea. J Korean Med Assoc. 2002; 45:356–360.

3. Mucke L. Neuroscience: Alzheimer's disease. Nature. 2009; 461:895–897.

4. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004; 53:474–481.

5. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014; 2:246–255.

6. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008; 2:1101–1113.

7. Heydemann A. An overview of murine high fat diet as a model for type 2 diabetes mellitus. J Diabetes Res. 2016; 2016:2902351.

8. Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. Front Neurosci. 2014; 8:375.

9. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Obesity, diabetes and cognitive deficit: the framingham heart study. Neurobiol Aging. 2005; 26:Suppl 1. 11–16.

10. Prickett C, Brennan L, Stolwyk R. Examining the relationship between obesity and cognitive function: a systematic literature review. Obes Res Clin Pract. 2015; 9:93–113.

11. Moreira PI. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis. 2012; 30:Suppl 2. S199–S215.

12. Walker JM, Harrison FE. Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer's disease: impacts on cognitive decline. Nutrients. 2015; 7:7332–7357.

13. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002; 59:1258–1263.

14. Niu L, Han DW, Xu RL, Han B, Zhou X, Wu HW, et al. A high-sugar high-fat diet induced metabolic syndrome shows some symptoms of Alzheimer's disease in rats. J Nutr Health Aging. 2016; 20:509–513.

15. Ledreux A, Wang X, Schultzberg M, Granholm AC, Freeman LR. Detrimental effects of a high fat/high cholesterol diet on memory and hippocampal markers in aged rats. Behav Brain Res. 2016; 312:294–304.

16. Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, et al. Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. Mediators Inflamm. 2015; 2015:105828.

17. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8:595–608.

18. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014; 6:37.

19. Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun. 2014; 2:135.

20. Mullane K, Williams M. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesisbut what lies beyond. Biochem Pharmacol. 2013; 85:289–305.

21. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2:a006213.

22. Jeong DU, Oh JH, Lee JE, Lee J, Cho ZH, Chang JW, et al. Basal forebrain cholinergic deficits reduce glucose metabolism and function of cholinergic and GABAergic systems in the cingulate cortex. Yonsei Med J. 2016; 57:165–172.

23. Lu Y, Ren J, Cui S, Chen J, Huang Y, Tang C, et al. Cerebral glucose metabolism assessment in rat models of Alzheimer's disease: an 18F-FDG-PET study. Am J Alzheimers Dis Other Demen. 2016; 31:333–340.

24. Liguori C, Chiaravalloti A, Sancesario G, Stefani A, Sancesario GM, Mercuri NB, et al. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2016; 43:2040–2049.

25. Krell-Roesch J, Ruider H, Lowe VJ, Stokin GB, Pink A, Roberts RO, et al. FDG-PET and neuropsychiatric symptoms among cognitively normal elderly persons: the mayo clinic study of aging. J Alzheimers Dis. 2016; 53:1609–1616.

26. Campion D, Pottier C, Nicolas G, Le Guennec K, Rovelet-Lecrux A. Alzheimer disease: modeling an Aβ-centered biological network. Mol Psychiatry. 2016; 21:861–871.

27. Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011; 14:724–738.

28. Allaman I, Bélanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011; 34:76–87.

29. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443:787–795.

30. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis. 2007; 12:913–922.

31. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the rotterdam study. Neurology. 1999; 53:1937–1942.

32. Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, et al. Glucose levels and risk of dementia. N Engl J Med. 2013; 369:540–548.

33. Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp Gerontol. 2007; 42:10–21.

34. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis. 2005; 7:63–80.

35. Leng Y, Karlsson HK, Zierath JR. Insulin signaling defects in type 2 diabetes. Rev Endocr Metab Disord. 2004; 5:111–117.

36. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol. 2014; 220:T1–T23.

37. Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol. 2014; 2:65–75.

38. Banks WA. The source of cerebral insulin. Eur J Pharmacol. 2004; 490:5–12.

39. Gray SM, Meijer RI, Barrett EJ. Insulin regulates brain function, but how does it get there? Diabetes. 2014; 63:3992–3997.

40. Medhi B, Chakrabarty M. Insulin resistance: an emerging link in Alzheimer's disease. Neurol Sci. 2013; 34:1719–1725.

41. Goberdhan DC, Wilson C. The functions of insulin signaling: size isn't everything, even in Drosophila. Differentiation. 2003; 71:375–397.

42. de la Monte SM, Chen GJ, Rivera E, Wands JR. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci. 2003; 60:2679–2691.

43. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005; 26:916–943.

44. Plum L, Schubert M, Brüning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005; 16:59–65.

45. Kleinridders A, Ferris HA, Cai W, Kahn CR. nsulin action in brain regulates systemic metabolism and brain function. Diabetes. 2014; 63:2232–2243.

46. McNay EC. Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function. Curr Opin Pharmacol. 2007; 7:628–632.

47. Heni M, Kullmann S, Preissl H, Fritsche A, Häring HU. Impaired insulin action in the human brain: causes and metabolic consequences. Nat Rev Endocrinol. 2015; 11:701–711.

48. De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer's disease? Alzheimers Dement. 2014; 10:1 Suppl. S26–S32.

49. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008; 22:246–260.

50. Ho L, Yemul S, Knable L, Katsel P, Zhao R, Haroutunian V, et al. Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases. Int J Alzheimers Dis. 2012; 2012:321280.

51. Kang S, Kim CH, Jung H, Kim E, Song HT, Lee JE. Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling. Neuropharmacology. 2017; 113(Pt A):467–479.

52. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003; 100:4162–4167.

53. Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, et al. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004; 24:9632–9637.

54. Jeon S, Park JE, Lee J, Liu QF, Jeong HJ, Pak SC, et al. Illite improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease through Akt/CREB and GSK-3β phosphorylation in the brain. J Ethnopharmacol. 2015; 160:69–77.

55. Farr SA, Sandoval KE, Niehoff ML, Witt KA, Kumar VB, Morley JE, et al. Peripheral administration of GSK-3β antisense oligonucleotide improves learning and memory in SAMP8 and Tg2576 mouse models of Alzheimer's disease. J Alzheimers Dis. 2016; 54:1339–1348.

56. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004; 29:1326–1334.

57. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012; 69:29–38.

58. Smith KB, Smith MS. Obesity statistics. Prim Care. 2016; 43:121–135.

59. Pataky Z, Bobbioni-Harsch E, Golay A. Obesity: a complex growing challenge. Exp Clin Endocrinol Diabetes. 2010; 118:427–433.

60. Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013: a decade of body mass index, Alzheimer's disease, and dementia. J Alzheimers Dis. 2015; 43:739–755.

61. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014; 220:T47–T59.

62. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11:85–97.

63. Bijland S, Mancini SJ, Salt IP. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond). 2013; 124:491–507.

64. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014; 18:37–45.

65. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001; 7:947–953.

66. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007; 117:2621–2637.

67. Lee B, Shao J. Adiponectin and energy homeostasis. Rev Endocr Metab Disord. 2014; 15:149–156.

68. Maddineni S, Metzger S, Ocón O, Hendricks G 3rd, Ramachandran R. Adiponectin gene is expressed in multiple tissues in the chicken: food deprivation influences adiponectin messenger ribonucleic acid expression. Endocrinology. 2005; 146:4250–4256.

69. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol. 2012; 165:313–327.

70. Letra L, Santana I, Seiça R. Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines. Metab Brain Dis. 2014; 29:563–568.

71. Yang Y, Hu W, Jiang S, Wang B, Li Y, Fan C, et al. The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases. Biochim Biophys Acta. 2015; 1852:1887–1894.

72. Ramamurthy S, Ronnett GV. Developing a head for energy sensingsensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol. 2006; 574(Pt 1):85–93.

73. Girgis CM, Cheng K, Scott CH, Gunton JE. Novel links between HIFs, type 2 diabetes, and metabolic syndrome. Trends Endocrinol Metab. 2012; 23:372–380.

74. Jiang C, Kim JH, Li F, Qu A, Gavrilova O, Shah YM, et al. Hypoxiainducible factor 1α regulates a SOCS3-STAT3-adiponectin signal transduction pathway in adipocytes. J Biol Chem. 2013; 288:3844–3857.

75. Dienel GA, Cruz NF. Nutrition during brain activation: does cell-to-cell lactate shuttling contribute significantly to sweet and sour food for thought. Neurochem Int. 2004; 45:321–351.

76. Dienel GA, Hertz L. Glucose and lactate metabolism during brain activation. J Neurosci Res. 2001; 66:824–838.

77. Dhopeshwarkar GA, Mead JF. Fatty acid uptake by the brain. 3. Incorporation of (1-14C)oleic acid into the adult rat brain. Biochim Biophys Acta. 1970; 210:250–256.

78. Panov A, Orynbayeva Z, Vavilin V, Lyakhovich V. Fatty acids in energy metabolism of the central nervous system. Biomed Res Int. 2014; 2014:472459.

79. Schönfeld P, Reiser G. Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab. 2013; 33:1493–1499.

80. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015; 6:456–480.

81. Cossarizza A, Ferraresi R, Troiano L, Roat E, Gibellini L, Bertoncelli L, et al. Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat Protoc. 2009; 4:1790–1797.

82. Navarro-Yepes J, Burns M, Anandhan A, Khalimonchuk O, del Razo LM, Quintanilla-Vega B, et al. Oxidative stress, redox signaling, and autophagy: cell death versus survival. Antioxid Redox Signal. 2014; 21:66–85.

83. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011; 194:7–15.

84. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997; 82:291–295.

85. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem. 2002; 277:40302–40308.

86. Giraldo E, Lloret A, Fuchsberger T, Viña J. Aβ and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E. Redox Biol. 2014; 2:873–877.

87. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging. 2002; 23:655–664.

88. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006; 30:400–418.

89. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114:1752–1761.

90. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002; 5:561–568.

91. Butterfield DA, Swomley AM, Sultana R. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013; 19:823–835.

92. Savaskan NE, Ufer C, Kühn H, Borchert A. Molecular biology of glutathione peroxidase 4: from genomic structure to developmental expression and neural function. Biol Chem. 2007; 388:1007–1017.

93. Seghrouchni I, Drai J, Bannier E, Rivière J, Calmard P, Garcia I, et al. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. Clin Chim Acta. 2002; 321:89–96.

94. Esposito L, Raber J, Kekonius L, Yan F, Yu GQ, Bien-Ly N, et al. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci. 2006; 26:5167–5179.

95. Mailloux RJ, Bériault R, Lemire J, Singh R, Chénier DR, Hamel RD, et al. The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS One. 2007; 2:e690.

96. Mailloux RJ, Puiseux-Dao S, Appanna VD. Alpha-ketoglutarate abrogates the nuclear localization of HIF-1alpha in aluminum-exposed hepatocytes. Biochimie. 2009; 91:408–415.

97. Bianchetti A, Rozzini R, Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin. 2003; 19:350–353.

98. Stark AK, Pelvig DP, Jørgensen AM, Andersen BB, Pakkenberg B. Measuring morphological and cellular changes in Alzheimer's dementia: a review emphasizing stereology. Curr Alzheimer Res. 2005; 2:449–481.

99. Bhatti AB, Usman M, Ali F, Satti SA. Vitamin supplementation as an adjuvant treatment for Alzheimer's disease. J Clin Diagn Res. 2016; 10:OE07–OE11.

100. Song J, Hur BE, Bokara KK, Yang W, Cho HJ, Park KA, et al. Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model. Yonsei Med J. 2014; 55:689–699.

TOOLS

Similar articles